engaged in the activities listed in this announcement.

3. The purpose of the announcement is to utilize and build upon existing framework of TB control activities that the NTP has developed or initiated.

4. The NTP has been mandated by the Ministry of Health in Latvia to coordinate and implement TB treatment and control activities including Multi Drug Resistent TB (MDR–TB) within the country.

C. Funds

Approximately $105,000 is being awarded in FY 2002. The award will be made by September 1, 2002, for a 12-month budget period within a project period of up to five years.

D. Where to Obtain Additional Information

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from:

Angelia D. Hill, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office,

Centers for Disease Control and Prevention, 2920 Brandywine Road, MS E–09, Atlanta, GA 30341–4146, Telephone: (770) 488–2785, FAX: (770) 488–2688, E-mail: *aph8@cdc.gov.*

Program Guidance may be obtained from: Michael Qualls, Deputy Associate Director, International Activities, Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road Mailstop E–10, Atlanta, GA 30333, Telephone 404–639–8488, e-mail address: *muq1@cdc.gov.*

Dated: August 27, 2002.

Sandra R. Manning, CGFM,

Director, Procurement and Grants Office, Centers for Disease Control & Prevention.

[FR Doc. 02–22464 Filed 9–3–02; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Science and Regulation of Biological Products: From a Rich History to a Challenging Future; Public Symposium; Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public symposium; amendment.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of public symposium entitled ''Science and Regulation of Biological Products: From a Rich History to a Challenging Future.'' The public symposium was announced in the **Federal Register** of July 17, 2002 (67 FR 46993). The purpose of the symposium is to commemorate the 100th anniversary of the enactment of the Biologics Control Act, the first Federal law regulating biological products. The amendment is being made to reflect a change in the building location. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Gail Sherman, Center for Biologics Evaluation and Research (HFM–42), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–2000, or e-mail: *Sherman@cber.fda.gov.*

SUPPLEMENTARY INFORMATION: In the **Federal Register** of July 17, 2002, FDA announced that a public symposium entitled ''Science and Regulation of Biological Products: From a Rich History to a Challenging Future'' would be held on September 23 and 24, 2002, at the National Institutes of Health (NIH), Natcher Conference Center, Bldg. 45, 45 Center Dr., Bethesda, MD. On page 46993, in the first column, the *Location* section of this public symposium is amended to read as follows:

Location: The public symposium will be held at the National Institutes of Health (NIH), Warren Grant Magnuson Clinical Center, Bldg. 10, 10 Center Dr., Bethesda, MD 20892.

Dated: August 27, 2002.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 02–22409 Filed 9–3–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 02D–0368]

International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products; Draft Guidance for Industry on ''Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (90-Day) Toxicity Testing'' (VICH GL31); Request for Comments; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry (ι147) entitled ''Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (90-Day) Toxicity Testing'' (VICH GL31). This draft guidance has been developed by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). The objective of this draft guidance is to establish the minimum recommendations for an internationally harmonized 90-day repeat-dose testing strategy for identifying target organ toxicity and the no-observed adverse effect level (NOAEL) for toxicity of veterinary drug residues in human food based upon repeated dose 90-day toxicity studies for identifying target organ toxicity.

DATES: Submit written or electronic comments on the draft guidance by October 4, 2002 to ensure their adequate consideration in preparation of the final document. General comments on agency guidance documents are welcome at any time.

ADDRESSES: Submit written requests for single copies of the draft guidance document to the Communications Staff (HFV–12), Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

Submit written comments on the draft guidance document to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments.* Comments should be identified with the full title of the draft guidance and the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Louis T. Mulligan, Center for Veterinary Medicine (HFV–153), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6984, e-mail: *lmulliga@cvm.fda.gov.*

SUPPLEMENTARY INFORMATION:

I. Background

In recent years, many important initiatives have been undertaken by regulatory authorities and industry associations to promote the